凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
华兰生物(002007)公告正文

华兰生物工程股份有限公司2006年第一季度报告

公告日期 2006-04-18
股票简称:华兰生物 股票代码:002007
 
                  华兰生物工程股份有限公司2006年第一季度报告

      1     重要提示
           1.1   本公司董事会及其董事保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性负个别及连带责任。
           1.2   没有董事对季度报告内容的真实性、准确性、完整性无法保证或存在异议。
           1.3   所有董事均出席董事会。
           1.4   本报告期财务报告未经审计。
           1.5   公司负责人安康先生、主管会计工作负责人王启平先生声明:保证季度报告中财务报告的真实、完整。
      2     公司基本情况
    
     2.1   基本情况简介
         股票简称                                         华兰生物
         股票代码                                          002007
      上市证券交易所                                  深圳证券交易所
                               董事会秘书              证券事务代表         投资者关系管理负责人
           姓名                    范蓓                      /                       安康
         联系地址       河南省新乡市华兰大道甲1号            /            河南省新乡市华兰大道甲1号
           电话               0373-3519901                   /                   0373-3519901
           传真               0373-3519911                   /                   0373-3519911
         电子信箱         hualan@hualanbio.com               /              hualan@hualanbio.com
     2.2   财务资料
    
     2.2.1   主要会计数据及财务指标
                                                                                单位:(人民币)元
                                                                           本报告期末比上年度期末增
                               本报告期末                上年度期末
                                                                                   减(%)
          总资产                  691,251,082.90            699,992,855.66                    -1.25%
    股东权益(不含少数
                                  541,783,811.74            526,226,054.29                     2.96%
        股东权益)
        每股净资产                           5.39                      5.24                    2.86%
    调整后的每股净资产                       5.39                      5.23                    3.06%
                                                                            本报告期比上年同期增减
                                 报告期              年初至报告期期末
                                                                                     (%)
    经营活动产生的现金
                                  -20,436,450.30             -20,436,450.30                 -437.15%
         流量净额
         每股收益                            0.15                      0.15                   36.36%
      每股收益(注)                         0.15            -                         -
       净资产收益率                         2.87%                    2.87%        上升了1.34个百分点
    扣除非经常性损益后
                                            3.24%                    3.24%        上升了1.67个百分点
      的净资产收益率
       非经常性损益项目                                                              金额
    营业外收支净额                                                                     -2,339,839.41
    所得税影响                                                                            350,975.91
             合计                                                                      -1,988,863.50
     2.2.2   财务报表
     2.2.2.2    利润及利润分配表
    
     编制单位:华兰生物工程股份有限公司                 2006年12月                  单位:人民币元
                                        本期                                 上年同期
           项目
                               合并              母公司              合并               母公司
    一、主营业务收入         90,175,670.48      84,034,341.60       89,589,421.01
      减:主营业务成本       56,688,864.86      51,511,433.53       66,289,806.34
          主营业务税金
                                  6,696.17
    及附加
    二、主营业务利润(亏
                             33,480,109.45      32,522,908.07       23,299,614.67
    损以“-”号填列)
      加:其他业务利润
                                 13,865.28          13,865.28           13,333.33
    (亏损以“-”号填列)
      减:营业费用            6,588,404.65       6,507,284.65        7,729,149.78
          管理费用            6,106,750.26       5,609,418.77        5,790,120.25
          财务费用              115,727.50        -129,441.54          929,868.52
    三、营业利润(亏损
                             20,683,092.32      20,549,511.47        8,863,809.45
    以“-”号填列)
      加:投资收益(亏
                                                    93,571.99
    损以“-”号填列)
          补贴收入
          营业外收入             45,923.82          45,923.82               25.00
      减:营业外支出          2,385,763.23       2,385,763.23          187,741.75
    四、利润总额(亏损
                             18,343,252.91      18,303,244.05        8,676,092.70
    以“-”号填列)
      减:所得税              2,752,618.93       2,745,486.60        1,301,413.90
          少数股东损益           32,876.53
      加:未确认的投资
    损失本期发生额
    五、净利润(亏损以
                             15,557,757.45      15,557,757.45        7,374,678.80
    “-”号填列)
      加:年初未分配利
                            122,547,119.56     122,547,119.56      104,685,665.02
    润
          其他转入
    六、可供分配的利润      138,104,877.01     138,104,877.01      112,060,343.82
      减:提取法定盈余
    公积
          提取法定公益
    金
          提取职工奖励
    及福利基金
          提取储备基金
          提取企业发展
    基金
          利润归还投资
    七、可供投资者分配
                            138,104,877.01     138,104,877.01     112,060,343.82
    的利润
      减:应付优先股股
    利
          提取任意盈余
    公积
          应付普通股股
                                                                    26,800,000.00
    利
          转作资本(或
    股本)的普通股股利
    八、未分配利润          138,104,877.01     138,104,877.01       85,260,343.82
    利润表(补充资料)
      1.出售、处置部门
    或被投资单位所得收
    益
      2.自然灾害发生的
    损失
      3.会计政策变更增
    加(或减少)利润总
    额
      4.会计估计变更增
    加(或减少)利润总
    额
      5.债务重组损失
      6.其他
     法定代表人:安康                   主管会计机构负责人:王启平            会计机构负责人:桑莉
     2.3   报告期末股东总数及前十名无限售条件流通股东持股情况
    
          报告期末股东总数                                      9,467
    前十名无限售条件流通股股东持股情况
                                 期末持有无限售条件流通股股份数
          股东名称(全称)                                             种类(A、B、H股或其它)
                                             量(股)
    中国工商银行-国联安德盛小
                                           4,277,814.00                          A股
    盘精选证券投资基金
    中国工商银行-安信证券投资
                                           2,000,961.00                          A股
    基金
    中国工商银行-德盛稳健证券
                                           1,763,530.00                          A股
    投资基金
    交通银行-海富通精选证券投
                                           1,400,677.00                          A股
    资基金
    中国银行-海富通股票证券投
                                           1,212,634.00                          A股
    资基金
    中国银行-海富通收益增长证
                                           1,055,532.00                          A股
    券投资基金
    长江证券有限责任公司                    987,284.00                           A股
    华夏成长证券投资基金                    981,337.00                           A股
    中国银行-金鹰成份股优选证
                                            738,965.00                           A股
    券投资基金
    中国工商银行-汉鼎证券投资
                                            508,000.00                           A股
    基金
      3     管理层讨论与分析
     3.1   公司报告期内经营活动总体状况的简要分析
           报告期内,公司实现主营业务收入9,017.57万元,较去年同期增长0.65%;实现主营业务利润3,348.01万元,较去年增长了43.69%;实现净利润1,555.78万元,较去年同期增长了110.96%。公司净利润增长高于主营业务收入的增长体现了公司盈利能力的加强:一方面公司通过提高血浆综合利用程度和产品结构的调整等措施进一步加强公司的盈利能力,一方面公司主要产品人血白蛋白平均价格较2005年同期提高所致。
     3.1.1   占主营收入或主营业务利润总额10%以上的主营行业或产品情况
     √适用□不适用
    
                                                                              单位:(人民币)万元
                                           主营业务分行业情况
                            主营业务收入           主营业务成本               毛利率(%)
    生物药品制造业                   9,017.57               5,668.89                          37.14%
      其中:关联交易                     0.00                   0.00                           0.00%
                                           主营业务分产品情况
    人血白蛋白                       6,990.00               4,082.78                          41.59%
    静注丙球                           866.30                 702.86                          18.87%
    其他                             1,161.27                 883.25                          23.94%
      其中:关联交易                     0.00                   0.00                           0.00%
     3.1.2   公司经营的季节性或周期性特征
     □适用√不适用
     3.1.3   报告期利润构成情况(主营业务利润、其他业务利润、期间费用、投资收益、补贴
     收入与营业外收支净额在利润总额中所占比例与前一报告期相比的重大变动及原因的明)
     √适用□不适用
    
                                 金额(元)                     占利润总额比例
                                                                                       较前一报告
         项目
                                                                                        期增减%
                       2006年1-3月         2005年度       2006年1-3月     2005年度
    主营业务利润       33,480,109.45     120,074,846.70      182.52%       201.76%       -19.24%
    其它业务利润           13,865.28       1,276,147.37       0.08%         2.14%        -2.07%
    期间费用           12,810,882.41      60,799,509.28      69.84%        102.16%       -32.32%
    营业外收支净额     -2,339,839.41        -324,466.91      -12.76%        -0.55%       -12.21%
    利润总额           18,343,252.91      59,514,340.55
             1、本报告期主营业务利润占利润总额比重下降的原因是:本报告期较前一报告期营业外支出增加
    原因
             较大所致。
    说明
             2、本报告期营业外收支净额占利润总额比重上升主要原因是:固定资产报废导致营业外支出增加。
     3.1.4   主营业务及其结构与前一报告期相比发生重大变化的情况及原因说明
     □适用√不适用
     3.1.5   主营业务盈利能力(毛利率)与前一报告期相比发生重大变化的情况及其原因说明
     □适用√不适用
     3.2   重大事项及其影响和解决方案的分析说明
     开展投资者关系管理的具体情况
     1、公司重视投资者关系管理工作,由公司董事长安康先生担任投资者关系管理负责人,平时主要通过电话、传真、电子邮件等方式回答广大投资者的咨询,使其及时了解公司生产经营情况。
     2、2006年3月13日,公司通过全景网投资者关系互动平台以网络远程方式举行了2005年度报告说明会,就公司年报业绩、未来发展以及其他投资者关心的问题,与投资者进行了全面沟通交流。
     3、报告期内,公司接待了多家机构投资者的实地调研,公司高管向基金经理、分析师详细介绍了公司的生产经营、发展战略等各方面情况。其他重大事项及其影响和解决方案的分析说明公司二届十四次董事会审议通过了以2005年12月31日总股本10050万股为基数,拟向全体股东每10股派发现金5元(含税),该预案需提交公司2005年度股东大会审议,内容详见2006年3月6日《证券时报》和巨潮资讯网(www.cninfo.com.cn)上公司二届十四次董事会决议公告。
     3.3   会计政策、会计估计、合并范围变化以及重大会计差错的情况及原因说明 
     □适用√不适用
     3.4   经审计且被出具“非标意见”情况下董事会和监事会出具的相关说明
     □适用√不适用
     3.5   预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示及原因说明
     □适用√不适用
     3.6   公司对已披露的年度经营计划或预算的滚动调整情况
     □适用√不适用
     3.7   原非流通股东在股权分置改革过程中做出的特殊承诺及其履行情况
     √适用□不适用
    
         股东名称                          特殊承诺                         履约情况    承诺履行情况
                       1、若华兰生物2005年度经审计后的净利润较2004年增
                       长低于20%时或者华兰生物2005年度财务报告被出具
                       非标准无保留意见审计报告时,触发追送股份承诺条
                       款:由原非流通股股东将其执行对价安排后的存量股未达到履约条件
                       份中的165万股(相当于按照股权分置改革前流通股
                       3300万股每10股追送0.5股)向无限受条件的流通股股
    全体原非流通股东
                       东追送股份。
                       2、在实施股权分置改革方案之后,将向2005年度股东
                       大会提出如下分红议案,并保证在股东大会表决时对
                       该议案投赞成票:华兰生物2005年度的利润分配比例        履约中     严格履行承诺
                       将不低于2005年度实现的可分配利润(非累计可分配
                       利润)的70%。
                       自改革方案实施之日起,至少在十二个月内不上市交
                       易或者转让,并在该期限届满后12个月内,若通过深
                       圳证券交易所交易系统出售华兰生物股票,出售价格
    新乡市华兰生物技术
                       不低于12.25元。同时,当华兰生物派发红股、转增股       履约中     严格履行承诺
    有限公司
                       本、增资扩股(包括可转换债券转换的股本)、配股、
                       派息等情况使股份数量或股东权益发生变化时,相应
                       调整最低出售价格。
                       自改革方案实施之日起,至少在十二个月内不上市交
    北京东方世辰生物技 易或者转让,并在该期限届满后24个月内,通过证券
                                                                             履约中     严格履行承诺
    术有限公司         交易所挂牌交易出售股份,出售数量占其所持有本公
                       司股份总数的比例,在每季度不超过百分之二十。
                       自改革方案实施之日起,至少在十二个月内不上市交
    成都夸常科技有限公易或者转让,并在该期限届满后24个月内,通过证券
                                                                             履约中     严格履行承诺
    司                 交易所挂牌交易出售股份,出售数量占其所持有本公
                       司股份总数的比例,在每季度不超过百分之二十。
                       自改革方案实施之日起,至少在十二个月内不上市交
    新乡市纪龙广告有限易或者转让,并在该期限届满后24个月内,通过证券
                                                                             履约中     严格履行承诺
    公司               交易所挂牌交易出售股份,出售数量占其所持有本公
                       司股份总数的比例,在每季度不超过百分之二十。
     3.8   非经营性资金占用及清欠进展情况
     □适用√不适用
    
     4        附录
                                                       资产负债表
    编制单位:华兰生物工程股份有限公司                                                                金额单位:人民币元
                                                       期末数                                    期初数
               项        目                  合   并              母公司               合  并              母公司
    流动资产:
           货币资金                         159,118,352.98      122,125,650.28       199,053,202.77       152,651,188.91
           短期投资
           应收票据                          11,246,110.00       10,435,510.00        14,254,294.04        12,336,754.04
           应收股利
           应收利息
           应收账款                          76,057,880.43       73,811,909.58        55,525,516.50        52,541,387.90
           其他应收款                         6,264,893.92        6,130,419.35         6,691,663.10         6,598,608.96
           预付账款                        105,692,972.72        40,901,853.17       103,970,025.91       60,563,617.61
           应收补贴款
           存货                              86,124,205.75       71,302,334.06       100,931,576.53        86,463,186.91
           待摊费用                              66,023.24           66,023.24           165,058.16           165,058.16
         一年内到期的长期债权投资
           其他流动资产
              流动资产合计                  444,570,439.04      324,773,699.68       480,591,337.01       371,319,802.49
    长期投资
           长期股权投资                      7,274,999.99        87,084,406.20         4,275,000.00       83,990,834.21
           长期债权投资
    合并价差
              长期投资合计                    7,274,999.99       87,084,406.20         4,275,000.00        83,990,834.21
    固定资产
           固定资产原价                     221,067,057.64      147,817,320.33       220,842,295.56       153,718,865.01
           减:累计折旧                      60,198,707.23       57,790,333.87        61,144,006.29        59,953,138.75
           固定资产净值                     160,868,350.41       90,026,986.46       159,698,289.27        93,765,726.26
           减:固定资产减值准备
           固定资产净额                     160,868,350.41       90,026,986.46       159,698,289.27        93,765,726.26
           工程物资
           在建工程                          62,853,588.78       70,516,818.01        39,524,604.48        47,474,601.71
           固定资产清理
              固定资产合计                  223,721,939.19      160,543,804.47       199,222,893.75       141,240,327.97
    无形资产及其他资产:
           无形资产                          15,683,704.68       10,569,650.87        15,903,624.90        10,762,223.21
           长期待摊费用
           其他长期资产
         无形资产及其他资产合计              15,683,704.68       10,569,650.87        15,903,624.90        10,762,223.21
    递延税项:
          递延税款借项
          资产总计                          691,251,082.90      582,971,561.22       699,992,855.66       607,313,187.88
    法定代表人:安康                         主管会计工作负责人:王启平                    会计机构负责人:桑莉
    
                                                   资产负债表(续)
    编制单位:华兰生物工程股份有限公司                                                              金额单位:人民币元
                                                       期末数                                    期初数
               项        目                  合   并              母公司              合   并              母公司
    流动负债:
           短期借款                          30,000,000.00                            24,000,000.00
           应付票据                           8,267,840.00        7,867,840.00         3,629,275.00        3,629,275.00
           应付账款                          31,675,351.26        2,504,306.34        43,809,877.64       38,406,172.22
           预收账款                           1,815,005.15        1,622,805.15         2,488,463.45        1,661,663.45
           应付工资                               1,000.00                                 1,000.00
           应付福利费                        10,861,466.02       10,861,466.02        11,320,336.87       11,320,336.87
           应付股利
           应交税金                           4,020,403.84        4,105,209.40         7,984,213.25        8,035,584.98
           其他应交款                                 3.49                                   148.20
           其他应付款                        30,082,954.64        6,086,122.57        47,785,916.72        9,894,101.07
           预提费用                                                                       37,200.00
           预计负债
           一年内到期的长期负债
           其他流动负债
              流动负债合计                  116,724,024.40       33,047,749.48       141,056,431.13       72,947,133.59
    长期负债:
           长期借款
           应付债券
           长期应付款
           专项应付款                         8,140,000.00        8,140,000.00         8,140,000.00        8,140,000.00
           其他长期负债
              长期负债合计                    8,140,000.00        8,140,000.00         8,140,000.00        8,140,000.00
    递延税项:
           递延税款贷项
                 负债合计                   124,864,024.40       41,187,749.48       149,196,431.13       81,087,133.59
    少数股东权益                             24,603,246.76                            24,570,370.24
    股东权益
           股本                             100,500,000.00      100,500,000.00       100,500,000.00      100,500,000.00
           减:已归还投资
           股本净额                         100,500,000.00      100,500,000.00       100,500,000.00      100,500,000.00
           资本公积                         276,620,868.90      276,620,868.90       276,620,868.90      276,620,868.90
           盈余公积                          26,558,065.83       26,558,065.83        26,558,065.83       26,558,065.83
           其中:法定公益金                   8,886,470.50        8,886,470.50         8,886,470.50        8,886,470.50
           未分配利润                       138,104,877.01      138,104,877.01       122,547,119.56      122,547,119.56
        其中:拟分配现金股利                  50,250,000.00       50,250,000.00        50,250,000.00       50,250,000.00
              股东权益合计                  541,783,811.74      541,783,811.74       526,226,054.29      526,226,054.29
           负债和股东权益总计              691,251,082.90       582,971,561.22      699,992,855.66       607,313,187.88
    法定代表人:安康                         主管会计工作负责人:王启平                    会计机构负责人:桑莉
    
    
                                                           利润表
    编制单位:华兰生物工程股份有限公司                                                               金额单位:人民币元
                                                          2006年1-3月                            2005年1-3月
                   项        目                     合   并             母公司              合  并            母公司
    一、主营业务收入                               90,175,670.48      84,034,341.60       89,589,421.01
           减:主营业务成本                        56,688,864.86      51,511,433.53       66,289,806.34
                 主营业务税金及附加                     6,696.17
    二、主营业务利润(亏损以“-”号填列)          33,480,109.45      32,522,908.07       23,299,614.67
           加:其他业务利润(亏损以“-”号
         填列)                                        13,865.28          13,865.28           13,333.33
           减:营业费用                             6,588,404.65       6,507,284.65        7,729,149.78
                 管理费用                           6,106,750.26       5,609,418.77        5,790,120.25
                 财务费用                             115,727.50        -129,441.54          929,868.52
    三、营业利润(亏损以“-”号填列)              20,683,092.32      20,549,511.47        8,863,809.45
           加:投资收益(损失以“-”号填列)                              93,571.99
                 补贴收入
                 营业外收入                            45,923.82          45,923.82               25.00
           减:营业外支出                           2,385,763.23       2,385,763.23          187,741.75
    四、利润总额(亏损总额以“-”号填列)          18,343,252.91      18,303,244.05        8,676,092.70
           减:所得税                               2,752,618.93       2,745,486.60        1,301,413.90
            少数股东损益                               32,876.53
    五、净利润(净亏损以“-”号填列)              15,557,757.45      15,557,757.45        7,374,678.80
    补充资料:
                                                          2006年1-3月                            2005年1-3月
                      项  目                        合   并             母公司             合   并            母公司
    1.出售、处置部门或被投资单位所得收益
    2.自然灾害发生的损失
    3.会计政策变更增加(或减少)利润总额
    4.会计估计变更增加(或减少)利润总额
    5.债务重组损失
    6.其他
    法定代表人:安康                       主管会计工作的负责人:王启平                        会计机构负责人:桑莉
    
                                                     现金流量表
    编制单位:华兰生物工程股份有限公司                                                                金额单位:人民币元
                                                                                             2006年1-3月
                                   项        目                                        合并                 母公司
    一、经营活动产生的现金流量:
            销售商品、提供劳务收到的现金                                               85,775,074.85       78,957,274.85
            收到的税费返还                                                                523,195.63
            收到的其他与经营活动有关的现金                                                193,779.60          144,700.16
                                   现金流入小计                                        86,492,050.08       79,101,975.01
            购买商品、接受劳务支付的现金                                               67,323,002.88       51,107,525.10
            支付给职工以及为职工支付的现金                                              4,446,718.54        4,021,736.72
            支付的各项税费                                                             18,323,743.84       17,601,616.87
            支付的其他与经营活动有关的现金                                             16,835,035.12       13,172,322.33
                                   现金流出小计                                       106,928,500.38       85,903,201.02
                           经营活动产生的现金流量净额                                 -20,436,450.30       -6,801,226.01
    二、投资活动产生的现金流量:
            收回投资所收到的现金
            取得投资收益所收到的现金
            处置固定资产、无形资产和其他长期资产所收到的现金                               81,500.00           81,500.00
            收到的其他与投资活动有关的现金
                                   现金流入小计                                            81,500.00           81,500.00
            购建固定资产、无形资产和其他长期资产所支付的现金                          22,579,899.49       20,805,812.62
            投资所支付的现金                                                            3,000,000.00        3,000,000.00
            支付的其他与投资活动有关的现金
                                   现金流出小计                                        25,579,899.49       23,805,812.62
                           投资活动产生的现金流量净额                                 -25,498,399.49      -23,724,312.62
    三、筹资活动产生的现金流量
            吸收投资所收到的现金
            借款所收到的现金                                                           30,000,000.00
            收到的其他与筹资活动有关的现金
                                   现金流入小计                                        30,000,000.00
            偿还债务所支付的现金                                                       24,000,000.00
            分配股利、利润或偿付利息所支付的现金
            支付的其他与筹资活动有关的现金
                                   现金流出小计                                        24,000,000.00
                           筹资活动产生的现金流量净额                                   6,000,000.00
    四、汇率变动对现金的影响
    五、现金及现金等价物净增加额                                                      -39,934,849.79      -30,525,538.63
    法定代表人:安康                        主管会计工作的负责人:王启平                       会计机构负责人:桑莉
    
    补充资料:
                                                                                             2006年1-3月
                                     项    目                                          合并                母公司
    1、将净利润调节为经营活动现金流量:
           净利润                                                                     15,557,757.45        15,557,757.45
           加:少数股东损益                                                               32,876.53
           加:计提的资产减值准备                                                         -8,909.40
               固定资产折旧                                                            4,178,221.77         2,960,715.95
               无形资产摊销                                                              219,920.22           192,572.34
               长期待摊费用摊销
               待摊费用减少(减:增加)                                                   99,034.92            99,034.92
               预提费用增加(减:减少)
               处置固定资产、无形资产和其他长期资产的损失(减:收益)                    -44,906.32           -44,906.32
               固定资产报废损失                                                        2,163,418.10         2,163,418.10
               财务费用                                                                  309,506.90            15,541.12
               投资损失(减:收益)                                                                           -93,571.99
               递延税款贷项(减:借项)
               存货的减少(减:增加)                                                 14,809,630.33        15,160,852.85
               经营性应收项目的减少(减:增加)                                      -19,793,002.43       -18,862,229.43
               经营性应付项目的增加(减:减少)                                      -37,959,998.37       -23,950,411.00
               其他
                           经营活动产生的现金流量净额                                -20,436,450.30        -6,801,226.01
    2、不涉及现金收支的投资和筹资活动:
           债务转为资本
           一年内到期的可转换公司债券
           融资租入固定资产
    3、现金及现金等价物净增加情况:
           现金的期末余额                                                            159,118,352.98       122,125,650.28
           减:现金的期初余额                                                        199,053,202.77       152,651,188.91
           加:现金等价物的期末余额
           减:现金等价物的期初余额
           减:首次合并子公司的现金期初余额
           现金及现金等价物净增加额                                                  -39,934,849.79       -30,525,538.63
    法定代表人:安康                   主管会计工作的负责人:王启平                       会计机构负责人:桑莉
    
    利润表附表
                                                      利润分配表
    编制单位:华兰生物工程股份有限公司                                                      金额单位:人民币元
                            项         目                            2006年1-3月               2005年1-3月
    一、净利润                                                           15,557,757.45                7,374,678.80
         加:年初未分配利润                                             122,547,119.56              104,685,665.02
             其他转入
    二、可供分配的利润                                                  138,104,877.01              112,060,343.82
         减:提取法定盈余公积
             提取法定公益金
    三、可供投资者分配的利润                                            138,104,877.01              112,060,343.82
         减:应付优先股股利
             提取任意盈余公积
             应付普通股股利                                                                          26,800,000.00
             整体变更未分配利润折股数
    四、未分配利润                                                      138,104,877.01               85,260,343.82
    法定代表人:安康                    主管会计工作的负责人:王启平                       会计机构负责人:桑莉
    
    华兰生物工程股份有限公司
    董事长:安康
    二○○六年四月十八日
    
数据加载中...
prevnext
手机查看股票